Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Toripalimab in India, marking the country as the third globally to access this groundbreaking immuno-oncology drug after the United States and China. Toripalimab, marketed under the brand name Zytorvi®, is the first and only immunotherapy approved by leading regulatory bodies, including the USFDA, EMA, and India’s DCGI, for treating recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
Developed in collaboration with Shanghai Junshi Biosciences, the drug demonstrated a 48% reduction in the risk of disease progression or death when combined with standard chemotherapy. This launch aims to address a significant unmet need in India, which reports a high burden of NPC cases, especially in the northeastern states.
Dr. Reddy’s continues to prioritize oncology with an ecosystem of innovative cancer therapies and collaborations for novel molecules. CEO M.V. Ramana emphasized this milestone as part of the company’s commitment to improving cancer care access in emerging markets.
Disclaimer: This report is based on a press release and is for informational purposes only. It should not be considered medical or investment advice.
